These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 19414814)

  • 1. Adenovirus vector-induced immune responses in nonhuman primates: responses to prime boost regimens.
    Tatsis N; Lasaro MO; Lin SW; Haut LH; Xiang ZQ; Zhou D; Dimenna L; Li H; Bian A; Abdulla S; Li Y; Giles-Davis W; Engram J; Ratcliffe SJ; Silvestri G; Ertl HC; Betts MR
    J Immunol; 2009 May; 182(10):6587-99. PubMed ID: 19414814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors.
    McCoy K; Tatsis N; Korioth-Schmitz B; Lasaro MO; Hensley SE; Lin SW; Li Y; Giles-Davis W; Cun A; Zhou D; Xiang Z; Letvin NL; Ertl HC
    J Virol; 2007 Jun; 81(12):6594-604. PubMed ID: 17428852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers.
    Pinto AR; Fitzgerald JC; Giles-Davis W; Gao GP; Wilson JM; Ertl HC
    J Immunol; 2003 Dec; 171(12):6774-9. PubMed ID: 14662882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors.
    Santra S; Sun Y; Korioth-Schmitz B; Fitzgerald J; Charbonneau C; Santos G; Seaman MS; Ratcliffe SJ; Montefiori DC; Nabel GJ; Ertl HC; Letvin NL
    Vaccine; 2009 Sep; 27(42):5837-45. PubMed ID: 19660588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B.
    Yu S; Feng X; Shu T; Matano T; Hasegawa M; Wang X; Ma H; Li H; Li Z; Zeng Y
    Vaccine; 2008 Nov; 26(48):6124-31. PubMed ID: 18812199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.
    Lorin C; Vanloubbeeck Y; Baudart S; Ska M; Bayat B; Brauers G; Clarinval G; Donner MN; Marchand M; Koutsoukos M; Mettens P; Cohen J; Voss G
    PLoS One; 2015; 10(4):e0122835. PubMed ID: 25856308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses.
    Koup RA; Roederer M; Lamoreaux L; Fischer J; Novik L; Nason MC; Larkin BD; Enama ME; Ledgerwood JE; Bailer RT; Mascola JR; Nabel GJ; Graham BS; ;
    PLoS One; 2010 Feb; 5(2):e9015. PubMed ID: 20126394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys.
    Liu J; Ewald BA; Lynch DM; Denholtz M; Abbink P; Lemckert AA; Carville A; Mansfield KG; Havenga MJ; Goudsmit J; Barouch DH
    J Virol; 2008 May; 82(10):4844-52. PubMed ID: 18337575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model.
    Suh YS; Park KS; Sauermann U; Franz M; Norley S; Wilfingseder D; Stoiber H; Fagrouch Z; Heeney J; Hunsmann G; Stahl-Hennig C; Sung YC
    Vaccine; 2006 Mar; 24(11):1811-20. PubMed ID: 16274888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).
    Kibuuka H; Kimutai R; Maboko L; Sawe F; Schunk MS; Kroidl A; Shaffer D; Eller LA; Kibaya R; Eller MA; Schindler KB; Schuetz A; Millard M; Kroll J; Dally L; Hoelscher M; Bailer R; Cox JH; Marovich M; Birx DL; Graham BS; Michael NL; de Souza MS; Robb ML
    J Infect Dis; 2010 Feb; 201(4):600-7. PubMed ID: 20078213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of adenovirus-specific antibodies on adenoviral vector-induced, transgene product-specific T cell responses.
    Small JC; Haut LH; Bian A; Ertl HC
    J Leukoc Biol; 2014 Nov; 96(5):821-31. PubMed ID: 25082150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New insights on adenovirus as vaccine vectors.
    Lasaro MO; Ertl HC
    Mol Ther; 2009 Aug; 17(8):1333-9. PubMed ID: 19513019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae.
    Chen H; Xiang ZQ; Li Y; Kurupati RK; Jia B; Bian A; Zhou DM; Hutnick N; Yuan S; Gray C; Serwanga J; Auma B; Kaleebu P; Zhou X; Betts MR; Ertl HC
    J Virol; 2010 Oct; 84(20):10522-32. PubMed ID: 20686035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans.
    Bett AJ; Dubey SA; Mehrotra DV; Guan L; Long R; Anderson K; Collins K; Gaunt C; Fernandez R; Cole S; Meschino S; Tang A; Sun X; Gurunathan S; Tartaglia J; Robertson MN; Shiver JW; Casimiro DR
    Vaccine; 2010 Nov; 28(50):7881-9. PubMed ID: 20937317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early CD4+ T Cell Responses Are Associated with Subsequent CD8+ T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine Strategy.
    Lhomme E; Richert L; Moodie Z; Pasin C; Kalams SA; Morgan C; Self S; De Rosa SC; Thiébaut R
    PLoS One; 2016; 11(4):e0152952. PubMed ID: 27124598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable.
    De Rosa SC; Thomas EP; Bui J; Huang Y; deCamp A; Morgan C; Kalams SA; Tomaras GD; Akondy R; Ahmed R; Lau CY; Graham BS; Nabel GJ; McElrath MJ;
    J Immunol; 2011 Sep; 187(6):3391-401. PubMed ID: 21844392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination.
    Cheng C; Wang L; Gall JG; Nason M; Schwartz RM; McElrath MJ; DeRosa SC; Hural J; Corey L; Buchbinder SP; Nabel GJ
    PLoS One; 2012; 7(4):e33969. PubMed ID: 22496775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens.
    Asbach B; Kliche A; Köstler J; Perdiguero B; Esteban M; Jacobs BL; Montefiori DC; LaBranche CC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Landucci G; Forthal DN; Seaman MS; Hawkins N; Self SG; Sato A; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Francis J; Galmin L; Ding S; Heeney JL; Pantaleo G; Wagner R
    J Virol; 2016 Apr; 90(8):4133-4149. PubMed ID: 26865719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects.
    Gach JS; Gorlani A; Dotsey EY; Becerra JC; Anderson CT; Berzins B; Felgner PL; Forthal DN; Deeks SG; Wilkin TJ; Casazza JP; Koup RA; Katlama C; Autran B; Murphy RL; Achenbach CJ
    PLoS One; 2016; 11(8):e0160341. PubMed ID: 27500639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody responses to prime-boost vaccination with an HIV-1 gp145 envelope protein and chimpanzee adenovirus vectors expressing HIV-1 gp140.
    Emmer KL; Wieczorek L; Tuyishime S; Molnar S; Polonis VR; Ertl HC
    AIDS; 2016 Oct; 30(16):2405-2414. PubMed ID: 27525550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.